Fig 5D and 5E illustrated that both GPC5 and DLGAP1 are the neo-loop involved genes, in which DLGAP1 gene affects the growth rate of hematopoietic cells [22] and GPC5 is a promising therapeutic target for reducing podocyte vulnerability in glomerular disease [23]. This evidence concerns the gene DLGAP1 and glomerular disorder.